CD274 and non-small cell lung carcinoma: In NSCLC patients with TPS of >50% the response rate to pembrolizumab is 44.8% and in NSCLC patients with PD-L1 <50% the response to pembrolizumab-chemotherapy combination is 56.7% [12, 13].